Every cancer patient deserves the right treatment
for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Dr. Raphael Gruber joins 2cureX as new Medical Director
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat tests determine the sensitivity to different drug regimens for certain types of metastic colorectral cancer. Ask your doctor if it is possible to consider IndiTreat for your cancer.
2cureX expands distribution of IndiTreat® to Israel
2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management
Strengthening the IndiTreat® distribution in North Europe
Get notified on mail, when news or press releases are posted on our website